Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAHIL BAKSHI

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1659368199
CMS profile
30262
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$12,280.01

111 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAHIL BAKSHI

NPI 1659368199 · CMS profile ID 30262

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659368199?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAHIL BAKSHI, NPI 1659368199, CMS profile ID 30262. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659368199?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SAHIL BAKSHI, NPI 1659368199, CMS profile ID 30262. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659368199?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SAHIL BAKSHI, NPI 1659368199, CMS profile ID 30262, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1659368199?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

111 matching records · $12,280.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 111 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–111 of 111.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Actelion Pharmaceuticals US, Inc. $16.6802/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788529865 CMS
Janssen Pharmaceuticals, Inc $15.2902/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788529839 CMS
Amgen Inc. $15.3702/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825757253 CMS
Novartis Pharmaceuticals Corporation $13.6402/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812598427 CMS
United Therapeutics Corporation $18.6901/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839125481 CMS
Amgen Inc. $17.0801/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825757245 CMS
AstraZeneca Pharmaceuticals LP $14.1901/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830003297 CMS
Novartis Pharmaceuticals Corporation $18.2501/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812598429 CMS
Esperion Therapeutics, Inc. $13.0501/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838241659 CMS
Amgen Inc. $12.4201/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825757241 CMS
Janssen Pharmaceuticals, Inc $13.6401/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788529819 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $38,635.00 93
PY2020 $17,339.20 50
PY2021 $12,280.01 111
PY2022 $18,997.53 110
PY2023 $25,339.30 104
PY2024 $28,781.89 80
PY2025 $25,804.82 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $29,570.00 19
PY2024 Principal investigator $65,398.00 38
PY2023 Principal investigator $121,534.62 53
PY2022 Principal investigator $79,209.61 27
PY2021 Principal investigator $43,687.00 21
PY2020 Principal investigator $98,498.14 14
PY2019 Principal investigator $22,850.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,270.00 12/22/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403850
Principal investigator 1 Janssen Research & Development, LLC $830.00 12/01/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403948
Principal investigator 1 Janssen Research & Development, LLC $1,436.00 10/27/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403868
Principal investigator 1 Janssen Research & Development, LLC $1,436.00 09/29/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403801
Principal investigator 1 Janssen Research & Development, LLC $1,270.00 09/04/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175404007
Principal investigator 1 Janssen Research & Development, LLC $3,370.00 08/21/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403886
Principal investigator 1 Janssen Research & Development, LLC $1,934.00 06/26/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403970
Principal investigator 1 Janssen Research & Development, LLC $1,270.00 05/26/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403796
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,250.00 05/22/2025 Covered Recipient Teaching Hospital
The Heart Hospital Baylor Plano
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225401947
Principal investigator 1 Janssen Research & Development, LLC $500.00 05/09/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403825
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $845.00 04/28/2025 Covered Recipient Teaching Hospital
The Heart Hospital Baylor Plano
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225401949
Principal investigator 1 Janssen Research & Development, LLC $1,270.00 04/28/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403791
Principal investigator 1 Janssen Research & Development, LLC $498.00 03/24/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403977
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 03/07/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403773
Principal investigator 1 Janssen Research & Development, LLC $2,540.00 03/03/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403928
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 02/24/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension PAH followed by an open label treatment period with macitentan and tadalafil fixed dose combination therapy No dispute reported 06/30/2026 1175403891
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 02/24/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension PAH followed by an open label treatment period with macitentan and tadalafil fixed dose combination therapy No dispute reported 06/30/2026 1175403966
Principal investigator 1 Janssen Research & Development, LLC $498.00 01/27/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403814
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 01/17/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175403953